Related references
Note: Only part of the references are listed.Phosphopeptide Analysis Reveals Two Discrete Clusters of Phosphorylation in the N-Terminus and the Roc Domain of the Parkinson-Disease Associated Protein Kinase LRRK2
Christian Johannes Gloeckner et al.
JOURNAL OF PROTEOME RESEARCH (2010)
Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2
Jason P. Covy et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites
Elisa Greggio et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
Juan M. Garcia-Martinez et al.
BIOCHEMICAL JOURNAL (2009)
Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease
R. Jeremy Nichols et al.
BIOCHEMICAL JOURNAL (2009)
Identification of the Autophosphorylation Sites of LRRK2
Shogo Kamikawaji et al.
BIOCHEMISTRY (2009)
Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease
Saskia Biskup et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2009)
Investigation of leucine-rich repeat kinase 2
Vasanti S. Anand et al.
FEBS JOURNAL (2009)
LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model
Javier Alegre-Abarrategui et al.
HUMAN MOLECULAR GENETICS (2009)
Characterization of Rictor Phosphorylation Sites Reveals Direct Regulation of mTOR Complex 2 by S6K1
Christian C. Dibble et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
Florence I. Raynaud et al.
MOLECULAR CANCER THERAPEUTICS (2009)
The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901
Stephen D. Barrett et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Solid Tumor Proteome and Phosphoproteome Analysis by High Resolution Mass Spectrometry
Sara Zanivan et al.
JOURNAL OF PROTEOME RESEARCH (2008)
LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study
Mary M. Hulihan et al.
LANCET NEUROLOGY (2008)
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study
Daniel G. Healy et al.
LANCET NEUROLOGY (2008)
Identification of RIP1 kinase as a specific cellular target of necrostatins
Alexei Degterev et al.
NATURE CHEMICAL BIOLOGY (2008)
The selectivity of protein kinase inhibitors: a further update
Jenny Bain et al.
BIOCHEMICAL JOURNAL (2007)
LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity
Mahaboobi Jaleel et al.
BIOCHEMICAL JOURNAL (2007)
BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo
Martin Steegmaier et al.
CURRENT BIOLOGY (2007)
Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors
Krista B. Goodman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo
Gopal P. Sapkota et al.
BIOCHEMICAL JOURNAL (2007)
Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase
Sheldon Holder et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Characterization of a protein kinase B inhibitor in vitro and in insulin-treated liver cells
Lisa Logie et al.
DIABETES (2007)
Transfection of mammalian cells using linear polyethylenimine is a simple and effective means of producing recombinant adeno-associated virus vectors
Sharon E. Reed et al.
JOURNAL OF VIROLOGICAL METHODS (2006)
Inhibition of Tp12 kinase and TNFα production with quinoline-3-carbonitriles for the treatment of rheumatoid arthritis
Yonghan Hu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin
Elisa Greggio et al.
NEUROBIOLOGY OF DISEASE (2006)
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Qi-Wen Fan et al.
CANCER CELL (2006)
Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach
IR Hardcastle et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase
P Gaillard et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1
RI Feldman et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine
YC Song et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo
EA Harrington et al.
NATURE MEDICINE (2004)
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins
LS Harrington et al.
JOURNAL OF CELL BIOLOGY (2004)
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease
C Paisán-Ruíz et al.
NEURON (2004)
Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology
A Zimprich et al.
NEURON (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Novel IKK inhibitors:: β-carbolines
AC Castro et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
A single amino acid difference between α and β Ca2+/calmodulin-dependent protein kinase kinase dictates sensitivity to the specific inhibitor, STO-609
H Tokumitsu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo
DB Ring et al.
DIABETES (2003)
BMS-345541 is a highly selective inhibitor of IκB kinase that binds at an allosteric site of the enzyme and blocks NF-κB-dependent transcription in mice
JR Burke et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site
C Pargellis et al.
NATURE STRUCTURAL BIOLOGY (2002)
The protein kinase A inhibitor H89 acts on cell morphology by inhibiting rho kinase
J Leemhuis et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
BL Bennett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Role of AMP-activated protein kinase in mechanism of metformin action
GC Zhou et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
SU6656, a selective Src family kinase inhibitor, used to probe growth factor signaling
RA Blake et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Share Paper
